Non-alcoholic Steatohepatitis

Infectious Disease·MeSH: Non-alcoholic Fatty Liver Disease

Prevalence

5000.0 / 100K

Incidence

500.0 / 100K/yr

15 drugs in development·12 companies·6 clinical trials

Drug Pipeline by Phase

Phase 3(4)

Drug	Company
cenicriviroc	Allergan plc (AGN)
mgl-3196	MADRIGAL PHARMACEUTICALS, INC. (MDGL)
Pitolisant oral tablets	Crinetics Pharmaceuticals, Inc. (CRNX)
Vortioxetine tablets	Crinetics Pharmaceuticals, Inc. (CRNX)

Phase 2(4)

Drug	Company
MLR-1023	Adhera Therapeutics, Inc. (ATRX)
nnc0174 0833	Novo Nordisk A/S (NVO)
nnc0194 0499	Novo Nordisk A/S (NVO)
rencofilstat (formerly CRV431)	Hepion Pharmaceuticals, Inc. (CTRVP)

Phase 1(4)

Drug	Company
ACT500 tablets	Crinetics Pharmaceuticals, Inc. (CRNX)
ARO-HSD Injection	ARROWHEAD PHARMACEUTICALS, INC. (ARWR)
cotadutide	ASTRAZENECA PLC (AZN)
miricorilant	CORCEPT THERAPEUTICS INC (CORT)

Preclinical(2)

Drug	Company
electroceuticals therapeutic devices	ENDONOVO THERAPEUTICS, INC. (ENDV)
siRNA targeting Beta2-spectrin	Bullfrog AI Holdings Inc. (BFRG)

Phase 1/Phase 2(1)

Drug	Company
ft-8225	Forma Therapeutics Holdings, Inc. (FMTX)

BioSniper tracks 15 drugs in development for Non-alcoholic Steatohepatitis across 12 companies.

There are 6 clinical trials targeting Non-alcoholic Steatohepatitis tracked by BioSniper.

The estimated prevalence of Non-alcoholic Steatohepatitis is approximately 5000.0 per 100,000 population.

Full trial data, competitive analysis, and AI-powered pipeline tracking.